logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10202339 B1

PDFFull Text
Date of Patent:
Feb. 12, 2019

Filed:

Oct. 11, 2013

Therapeutic compounds and compositions

Applicant:

Agios Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Janeta Popovici-Muller, Windham, NH (US);

Francesco G. Salituro, Marlborough, MA (US);

Jeffrey O. Saunders, Lincoln, MA (US);

Jeremy Travins, Southborough, MA (US);

Shunqi Yan, Irvine, CA (US);

Assignee:

Agios Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:

Goodwin Procter LLP

Primary Examiner:

D Margaret M Seaman

Int. Cl.
CPC ...
C07C 311/44 (2006.01); A61K 31/17 (2006.01); A61K 31/18 (2006.01); A61K 31/351 (2006.01); A61K 31/381 (2006.01); A61K 31/397 (2006.01); A61K 31/422 (2006.01); A61K 31/4402 (2006.01); A61K 31/4406 (2006.01); A61K 31/4436 (2006.01); A61K 31/505 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); C07D 213/40 (2006.01); C07D 213/74 (2006.01); C07D 239/42 (2006.01); C07D 267/10 (2006.01); C07D 295/26 (2006.01); C07D 309/14 (2006.01); C07D 333/20 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01);
U.S. Cl.
CPC ...
C07C 311/44 (2013.01); A61K 31/17 (2013.01); A61K 31/18 (2013.01); A61K 31/351 (2013.01); A61K 31/381 (2013.01); A61K 31/397 (2013.01); A61K 31/422 (2013.01); A61K 31/4402 (2013.01); A61K 31/4406 (2013.01); A61K 31/4436 (2013.01); A61K 31/505 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); C07D 213/40 (2013.01); C07D 213/74 (2013.01); C07D 239/42 (2013.01); C07D 267/10 (2013.01); C07D 295/26 (2013.01); C07D 309/14 (2013.01); C07D 333/20 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01);
Abstract

Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).

Find Patent Forward Citations

Loading…